Building on the results of the Hit-to-Lead stage, our goal is to refine molecular structures to achieve optimal pharmacological and physicochemical profiles suitable for in vivo evaluation: a new preclinical candidate has been born.
The lead optimization process involves three critical components: Enhancing the binding affinity to the receptor, optimizing ADMET (absorption, distribution, metabolism, excretion and toxicity) properties and assessing the synthetic feasibility of the future lead candidate.
We emphasize data-driven decision-making and close collaboration between chemistry, biology, and pharmacokinetics teams. This integrated workflow allows us to identify liabilities early, mitigate safety risks, and streamline progression toward IND-enabling studies.
Each program is tailored to the client’s strategic objectives — whether focusing on rapid optimization for proof-of-concept studies or comprehensive development of a fully characterized preclinical candidate. Our flexible infrastructure and experienced scientists ensure efficient project execution and transparent communication throughout the process.
Our Lead optimization service delivers high-quality, well-characterized compounds ready for preclinical development, reducing attrition and accelerating the path from discovery to the clinic.
